C. Lister

发表

Antidiabetic Efficacy of BRL 49653, a Potent Orally Active Insulin Sensitizing Agent, Assessed in the C57BL/KsJ db/db Diabetic Mouse by Non‐invasive 1H NMR Studies of Urine

S. Connor, S. Smith, M. G. Hughes, 1997, The Journal of pharmacy and pharmacology.

Repeat Treatment of Obese Mice With BRL 49653, a New Potent Insulin Sensitizer, Enhances Insulin Action in White Adipocytes: Association With Increased Insulin Binding and Cell-Surface GLUT4 as Measured by Photoaffinity Labeling

J. Holder, Stephen A. Smith, M. Cawthorne, 1995, Diabetes.

Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice.

J. Holder, J. Clapham, V. Piercy, 2001, Biochemical and biophysical research communications.

v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fatty rats.

V. H. Maier, G. Gould, H. Chapman, 2000, Diabetes.

Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues

V. Emilsson, M. Cawthorne, J. R. Arch, 1999, FEBS letters.

Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone.

X. Cai, G. Williams, J. R. Arch, 2000, Brain research. Molecular brain research.

Hypoglycemia activates orexin neurons and selectively increases hypothalamic orexin-B levels: responses inhibited by feeding and possibly mediated by the nucleus of the solitary tract.

X. Cai, Shelagh Wilson, M. Evans, 2001, Diabetes.

[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.

Stephen A. Smith, M. Cawthorne, S. Smith, 1994, Journal of medicinal chemistry.

Non thiazolidinedione antihyperglycaemic agents. 2: α-Carbon substituted β-phenylpropanoic acids1

David Haigh, Stephen A. Smith, M. Cawthorne, 1996 .

Non thiazolidinedione antihyperglycaemic agents. 1: α-Heteroatom substituted β-phenylpropanoic acids

David Haigh, Stephen A. Smith, M. Cawthorne, 1996 .

Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean

Martin D. Brand, Mark Skehel, Sohaila Rastan, 2000, Nature.

Improved Glycemic Control in C57BI/KsJ (db/db) Mice After Treatment with the Thermogenic β-Adrenoceptor Agonist, BRL 26830

M. Sennitt, M. Cawthorne, C. Lister, 1985, Diabetes.

35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts.

Thomas J. Smith, B. M. Rasmussen, V. C. Phan, 1999, Diabetologia.

Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter.

J. Holder, M. Coghlan, J. Clapham, 2004, Metabolism: clinical and experimental.

Non-thiazolidinedione antihyperglycaemic agents. Part 3 : The effects of stereochemistry on the potency of α-methoxy-β-phenylpropanoic acids

Stephen A. Smith, J. Holder, D. Eggleston, 1999 .

Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat

C. Lister, R. Buckingham, R. E. Buckingham, 2000, Diabetes, obesity & metabolism.